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Vascular smooth muscle (VSM) is unique in its ability to maintain an intrinsic level
of contractile force, known as tone. Vascular tone is believed to arise from the
constitutive activity of membrane-bound L-type Ca2+ channels (LTCC). This study
used a pharmacological agonist of LTCC, Bay K8644, to elicit a sustained, sub-
maximal contraction in VSM that mimics tone. Downstream signaling was investigated
in order to determine what molecules are responsible for tone. Medial strips of swine
carotid artery were stimulated with 100 nM Bay K8644 to induce a sustained level
of force. Force and phosphorylation levels of myosin light chain (MLC), MAP kinase,
MYPT1, CPI-17, and caldesmon were measured during Bay K8644 stimulation in the
presence and absence of nifedipine, ML-7, U0126, bisindolylmaleimide (Bis), and H-
1152. Nifedipine and ML-7 inhibited force and MLC phosphorylation in response to Bay
K8644. Inhibition of Rho kinase (H-1152) but not PKC (Bis) inhibited Bay K8644 induced
force. U0126 significantly increased Bay K8644-dependent force with no effect on MLC
phosphorylation. Neither CPI-17 nor caldesmon phosphorylation were increased during
the maintenance of sustained force. Our results suggest that force due to the influx
of calcium through LTCCs is partially MLC phosphorylation-dependent but does not
involve PKC or caldesmon. Interestingly, inhibition of MLC kinase (MLCK) and PKC
significantly increased MAP kinase phosphorylation suggesting that MLCK and PKC
may directly or indirectly inhibit MAP kinase activity during prolonged contractions
induced by Bay K8544.
Keywords: carotid artery, Bay K8644, nifedipine, myosin light chain kinase, protein kinase C, MAP kinase, Rho
kinase
INTRODUCTION
Vascular smooth muscle (VSM) contraction is initiated by an increase in intracellular Ca2+ via
influx through plasma membrane ion channels or release from the sarcoplasmic reticulum (Somlyo
and Somlyo, 1968). Once in the cytoplasm, Ca2+ binds with calmodulin in order to activate myosin
light chain (MLC) kinase. This leads to phosphorylation of the regulatory MLC at Ser19, interaction
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between actin and myosin filaments, and contraction (Conti and
Adelstein, 1981; Dillon et al., 1981). While the influx of Ca2+
and phosphorylation of MLC are required for the initiation of
smooth muscle contraction, it is not clearly understood how force
is sustained over time. There appears to be a complex, highly
nuanced intracellular signaling network that can finely tune the
level of maintained force in order to meet the ever-changing
circulatory demands of an organism (Horowitz et al., 1996; Davis
and Hill, 1999).
Vascular smooth muscle contractile force can be modulated
by Ca2+ sensitization or thin filament disinhibition. Ca2+
sensitization involves inhibition of the MLC phosphatase such
that the cell can maintain levels of MLC phosphorylation
without additional cytosolic Ca2+ or activation of MLC
kinase. Rho kinase (ROCK), activated by GTP-bound RhoA,
phosphorylates and inhibits the myosin-binding subunit of the
MLC phosphatase, a protein known as MYPT1 (Kimura et al.,
1996). Additionally, protein kinase C (PKC) phosphorylates
the 17 kDa protein kinase C-potentiated myosin phosphatase
inhibitor (CPI-17) which, when phosphorylated, binds to
and inhibits the MLC phosphatase (Eto et al., 1995). Thin
filament disinhibition involves phosphorylation of caldesmon
that relieves inhibition of myosin ATPase. The involvement
of either of these modulatory pathways is not entirely
understood but they are thought to contribute to VSM
tone.
Tone is a variable amount of VSM contractile force that
exists in the presence of sub-maximal stimulation (Folkow, 1989).
A feature of tone is that the intracellular Ca2+ concentration
([Ca2+]i) is higher than during a relaxed state but significantly
lower than during a stimulated contractile event (Rubart et al.,
1996). This small amount of Ca2+ in the cytoplasm is thought
to be maintained by a balance of Ca2+ influx through calcium
channels and eﬄux via Ca2+ATPases and Na+/Ca2+ exchangers
in the plasma membrane (Nazer and van Breemen, 1998;
Thornloe and Nelson, 2005). The L-type Ca2+ channel (LTCC)
appears to be particularly important in maintaining VSM tone
(Moosmang et al., 2003; Cobine et al., 2007).
LTCC (also known as voltage-gated calcium channels, Cav1.2
channels, and dihydropyridine receptors) can respond to small
changes in membrane potential and do not require an action
potential to be opened (Fleischmann et al., 1994; Catterall, 2000;
Navedo et al., 2005). This allows LTCC to create a “calcium
window” that provides a small, sustained influx of Ca2+ into
the cell that can activate the contractile mechanism (Gollasch
et al., 1998; Fransen et al., 2012). Experimental evidence has
demonstrated a role for LTCC in VSM tone. A smooth muscle-
specific knockout of the gene for LTCC in mice resulted in
animals with reduced mean arterial pressure (Moosmang et al.,
2003). Another study showed that LTCC are upregulated in
genetic rodent models of hypertension (Sonkusare et al., 2006).
Human patients with an inherited form of hypertension also
exhibit increased expression of LTCC in their vasculature (Pesic
et al., 2004). Aberrations in the number or function of LTCC
appear to cause pathologic states of hypo- or hypertension
(Navedo et al., 2010), but how does this affect intracellular
signaling pathways?
The goal of this study was to use a pharmacological agonist of
LTCC, Bay K8644, to elicit a sustained, sub-maximal contraction
in VSM in order to study the effect on downstream signaling.
Inhibitors against proteins known or suspected to be involved
with modulation of force were used and the effects on force
and intracellular signaling were observed. The results were
in many ways unexpected and provided novel insight into
what mechanisms sustain force in response to increased LTCC
opening.
MATERIALS AND METHODS
Preparation of VSM Tissue
Swine carotid arteries were transported from a local
slaughterhouse to the laboratory in ice-cold physiological
salt solution (PSS) that contained all ingredients listed below
except glucose. Arteries were immediately cleaned of excess
connective tissue and fat, then stored in glucose-containing PSS
composed of (in mM): 140 NaCl, 4.7 KCl, 1.2 MgSO4, 1.6 CaCl2,
1.2 Na2HPO4, 2 MOPS (pH 7.4), 5 D-glucose, and 0.02 EDTA
at 4◦C for no longer than 4 days. Previous studies have shown
there is no loss of viability or contractile force with this storage
(Fulginiti et al., 1993; Katoch and Moreland, 1995; Smolock et al.,
2006). Prior to experimentation, adventitial and intimal layers
were carefully removed in order to obtain a strip composed
primarily of medial smooth muscle. Circumferential strips were
cut (2 mm × ∼6 mm) and placed in PSS at 4◦C until they were
mounted for measurement of isometric force.
Isometric Force Recordings
Circumferential strips of VSM were mounted in double-walled
glass muscle baths containing PSS bubbled with 100% oxygen
and maintained at 37◦C. Tissue strips were stretched to an
initial tension of 5 grams and allowed to equilibrate and stress-
relax to a baseline of approximately 1 g of passive tension;
this passive force has been previously shown to set the tissues
at a length that approximates Lo, a length within the length-
range for optimal active force development (Herlihy and Murphy,
1973). Following equilibration, tissues were contracted with
110 mM KCl-containing PSS (equimolar substitution for NaCl)
and relaxed with regular PSS. This contraction-relaxation cycle
was repeated four times until a stable maximum force value
was achieved. Isometric force was detected by Grass FT.03
force transducers and recorded using LabChart software (AD
Instruments, Colorado Springs, CO, USA). Tissues were treated
with one of the following inhibitors for 20 min: 1 µM nifedipine
(LTCC inhibitor), 10 µM ML-7 (MLC kinase inhibitor), 3 µM
bisindolylmaleimide I (Bis; PKC inhibitor; henceforth referred
to as Bis), 10 µM U0126 (MAP kinase kinase inhibitor), or
1 µM H-1152 (Rho kinase inhibitor). Following treatment with
inhibitors 100 nM of the LTCC agonist Bay K8644 was added
for 120 min. Measurements of protein phosphorylation were all
carried out in muscle tissues frozen at the 120 min time point.
Because LTCC are voltage-gated, experiments were conducted
in PSS containing 15 mM KCl, rather than the typical 4.7 mM
KCl. Preliminary studies showed that 15 mM KCl-containing
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PSS alone did not produce an increase in force. As shown in
several studies, the increased concentration of KCl created a
sufficient change in membrane voltage such that LTCC could be
activated by Bay K8644 (Gopalakrishnan et al., 1985; Alonso et al.,
1989; Navedo et al., 2005). At the conclusion of the experiment,
tissues were rapidly frozen in a slurry of 6% trichloroacetic
acid/acetone/10 mM dithiothreitol and dry ice at the 120 min
time point after stimulation.
Processing of Tissue Samples
Frozen VSM tissue strips were slowly thawed to room
temperature and then rinsed in 100% acetone to remove residual
traces of trichloroacetic acid. They were then air dried before
being pulverized in an ice-cold buffer solution of 1% SDS, 10%
glycerol, 50 mM Tris HCl (pH 6.8), 10 mM dithiothreitol, and
Protease Inhibitor Cocktail (Sigma, St. Louis, MO, USA) using
glass-glass homogenizers. Samples were stored at –80◦C until
subjected to SDS-polyacrylamide gel electrophoresis (PAGE).
Protein content of homogenized samples was determined using
a Lowry protein assay.
SDS-PAGE and Western Blotting
For detection of CPI-17 and MAP kinase phosphorylation, 20 µg
of each sample was loaded onto a 14% polyacrylamide separating
gel with a 4% stacking gel. For detection of MYPT1 and
caldesmon phosphorylation, 20 µg of each sample was loaded
onto an 8% polyacrylamide separating gel with a 4% stacking gel.
Gel electrophoresis was carried out at 200 V at room temperature
for 1 h or until the dye front reached the bottom of the gel.
Proteins were then transferred to a nitrocellulose membrane at
100 V for 1 h in a chilled buffer tank. Membranes were blocked
in a 1:1 solution of Odyssey Blocking Buffer (Licor, Lincoln,
NE, USA) and phosphate buffered saline (PBS, pH 7.4) at room
temperature for 1 h then incubated in primary antibodies diluted
in a 1:1 solution of Odyssey Blocking Buffer and PBS overnight
at 4◦C. Membranes were washed in PBS with 0.1% Tween five
times for 5 min each. Fluorescent secondary antibodies (goat
anti-mouse 800CW and goat anti-rabbit 680LT, Licor, Lincoln,
NE, USA) were used at a 1:10,000 dilution in a 1:1 solution of
Odyssey Blocking Buffer and PBS. Membranes were incubated in
secondary antibody at room temperature for 45 min followed by
five washes in PBS with 0.1% Tween for 5 min each.
Membranes were imaged using a Licor FC camera system and
optical densitometry of the bands was determined using Image
Studio software (Licor, Lincoln, NE).
Urea/Glycerol-PAGE
Thawed and dehydrated tissues were placed in sample buffer
containing 8 M urea, 18.5 mM Tris (pH 8.6), 20.4 mM glycine,
0.5 M dithiothreitol, 0.05% saturated sucrose, 0.2% bromophenol
blue, 0.4 M EDTA, and Protease Inhibitor Cocktail (Sigma,
St. Louis, MO, USA). Samples were gently rocked at room
temperature for approximately 2 h during which the MLC
were solubilized, then stored at 4◦C until subjected to gel
electrophoresis. A gel was prepared containing 18.5 % glycerol,
30% acrylamide with bisacrylamide (29:1), Tris (pH 8.6), glycine,
and water. The gel was subjected to pre-electrophoresis at 400 V
for 1 h. Samples were then loaded onto the gel, subjected to
electrophoresis at 400 V for 90 min, then transferred to a
nitrocellulose membrane at 25 V for 1 h. Western blotting was
carried out as described above for SDS-PAGE.
Chemicals and Antibodies
Drugs and inhibitors were dissolved either in deionized water
or dimethyl sulfoxide (DMSO) according to manufacturers’
instructions. Bay K8644 and ML-7 were obtained from Tocris
(Bristol, UK). Nifedipine was obtained from Sigma (St. Louis,
MO, USA). H-1152, U0126, and Bis, were ordered from
Calbiochem (Billerica, MA, USA). The following antibodies
were used for Western blotting: p42/44 MAPK (Millipore,
Billerica, MA, USA), phosphorylated p42/44 MAPKThr185/Tyr187
(Promega, Madison, WI), MLC (Sigma, St Louis, MO, USA),
phosphorylated MLCSer19 (Cell Signaling, Danvers, MA, USA),
CPI-17 (Santa Cruz, Santa Cruz, CA, USA), phosphorylated CPI-
17Thr38 (Santa Cruz, Santa Cruz, CA, USA), MYPT1 (Covance,
Conshohocken, PA, USA), phosphorylated MYPT1Thr850
(Millipore, Billerica, MA, USA), caldesmon (Sigma, St Louis,
MO, USA), and phosphorylated caldesmonSer789 (Millipore,
Billerica, MA, USA). Electrophoretic reagents were purchased
from Bio-Rad Laboratories (Hercules, CA, USA). All other
chemicals were analytical grade or better and purchased from
Fisher Scientific (Pittsburgh, PA, USA).
Statistical Analysis
Results are represented as mean ± SEM with n representing
the number of arteries. Statistical analysis was performed using
One-way ANOVA with the Holm–Sidak Method of comparing
experimental groups to Bay K8644-stimulated tissue. Time
course of force development was analyzed with a One Way
Repeated Measures ANOVA. A p-value less than 0.05 was
considered significant.
RESULTS
Bay K8644-Stimulated Force
The swine carotid artery exhibits little spontaneous tone therefore
a pharmacological approach was used to mimic tone in this
tissue. A dose-response curve of VSM contraction to the LTCC
agonist Bay K8644 (30, 100, 300, 1, 3, and 10 µM) was used to
determine the concentration(s) that produced sub-maximal force
(data not shown). A time course experiment revealed that Bay
K8644-induced force increased steadily for the first 60 min and
very slowly over the next 60 min. The optimal concentration
for sustained, sub-maximal force was determined to be 100 nM.
The magnitude of force development was normalized to the
maximum force produced by a tissue strip in response to 110 mM
KCl PSS. Bay K8644-induced force was approximately 60–70% of
maximal KCl-stimulated force, as shown in Figure 1. To study the
potential role of various signaling proteins in VSM contraction,
inhibitors against LTCC (nifedipine), MLC kinase (ML-7), PKC
(Bis), MAP kinase kinase (U0126), and Rho kinase (H-1152) were
added 20 min prior to stimulation with Bay K8644. Pre-treatment
with nifedipine (Figure 2A) or ML-7 (Figure 2B) prevented Bay
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FIGURE 1 | Time course of isometric contraction of swine carotid
smooth muscle stimulated by 100 nM of Bay K8644. Measurements of
plateau force and protein phosphorylation were done at the 120 min time
point.
K8644-induced force development. Inhibition of ROCK by H-
1152 (Figure 2C) also prevented force development suggesting
that ROCK activity is required for initiation of membrane
depolarization-induced force. Inhibition of PKC with Bis did
not significantly alter Bay K8644-stimulated force (Figure 2D)
suggesting that PKC activity is not required for force initiation
or maintenance in response to opening LTCC. Pre-treatment
with the MAP kinase kinase inhibitor U0126 produced greater
sustained force than Bay K8644 stimulation without inhibitor
(Figure 2E) however, the rate of rise was the same (i.e., no
leftward shift of the curve). The finding that inhibition of MAP
kinase kinase increases sustained force suggests that MAP kinase
may have an inhibitory role in contraction, perhaps to keep the
tissue from unregulated maximal contractions. As can be seen at
zero time in the panels in Figure 2, basal, unstimulated force was
approximately 5–10% of the maximum response to 110 mM KCl.
Figure 3 shows the force developed in response to Bay K8644
alone and in the presence of the various inhibitors at the final
time point, 120 min after Bay K8644 stimulation. Consistent
with the time course data presented in Figure 2, inhibition of
LTCC, MLC kinase, and ROCK inhibited Bay K8644-induced
force whereas inhibition of MAP kinase kinase increased force in
response to Bay K8644. The statistical analysis comparing force
at this single time point found the increase during MAP kinase
kinase inhibition to be significant.
Myosin Light Chain Phosphorylation
Myosin light chain (MLC) phosphorylation at Ser19 was
assessed by urea/glycerol-PAGE. Urea/glycerol-PAGE
uses a high concentration of urea in the sample buffer to
solubilize MLC and separate them from the larger heavy chain
molecules. The glycerol gel is suitable for separating different
phosphorylation states of the same protein. Phosphorylated and
non-phosphorylated MLC have different electrophoretic
mobilities within the gel and appear as discrete bands.
A representative Western blot is shown in Figure 4A. Figure 4B
shows quantitative results of several such Western blots and
demonstrates that Bay K8644 significantly increased Ser19 MLC
phosphorylation. Nifedipine and ML-7 treatment prevented
any increase in Ser19 MLC phosphorylation above basal levels,
as expected. The MAP kinase kinase inhibitor U0126 had no
effect on Bay K8644-stimulated Ser19 MLC phosphorylation
levels in contrast to significantly increased Bay K8644-induced
force. The PKC and ROCK inhibitors (Bis and H-1152,
respectively) appeared to reduce the Bay K8644-stimulated
MLC phosphorylation to some extent, but failed to bring
the phosphorylation level back to the baseline. Due to the large
variation in data, it is difficult to draw any meaningful correlation
between the phosphorylation level and force production.
p42/44 MAP Kinase Phosphorylation
Activity of p42/44 MAP kinase was assessed by comparing
phosphorylation levels to basal unstimulated control values.
Figure 5A shows a representative Western blot of MAP
kinase phosphorylation in response to Bay K8644 without
inhibitor and in the presence of nifedipine, ML-7, Bis, U0126
or H-1152. Quantitation of several such blots is shown in
Figure 5B. Stimulation of the tissues with Bay K8644 did not
significantly increase MAP kinase phosphorylation above basal
levels, represented by the dashed line. The effectiveness of
U0126 to inhibit the MAP kinase kinase and therefore MAP
kinase phosphorylation is demonstrated by the nearly complete
abolishment of MAP kinase phosphorylation. Although Bay
K8644 alone did not increase MAP kinase phosphorylation, the
addition of either Bis to inhibit PKC or the addition of ML-
7 to inhibit MLC kinase significantly increased MAP kinase
phosphorylation levels. This was unexpected as PKC is thought to
activate MAP kinase in this tissue and MLC kinase has no known
role in the activation of MAP kinase. Inhibition of LTCC with
nifedipine had no effect on MAP kinase phosphorylation.
MYPT1 Phosphorylation
To determine the possible involvement of the MLC phosphatase
in sustaining VSM force, we measured phosphorylation of
the myosin binding subunit, MYPT1. Phosphorylation of
MYPT1 inhibits MLC phosphatase activity and allows for
maintained MLC phosphorylation and force. Figure 6A shows
a representative Western blot of MYPT1 phosphorylation in
response to stimulation with Bay K8644 without inhibitor and
in the presence of nifedipine, ML-7, Bis, U0126, or H-1152.
Figure 6B shows the quantitation of several such blots. The level
of MYPT1 phosphorylation decreased from basal levels (dashed
line) in response to Bay K8644 stimulation without inhibitor.
The inclusion of ML-7, Bis, or U0126 had no effect on MYPT1
phosphorylation as compared to Bay K8644 without inhibitor.
The ROCK inhibitor H-1152 abolished MYPT1 phosphorylation
as expected as ROCK is the primary kinase that catalyzes
MYPT1 phosphorylation. The level of MYPT1 phosphorylation
in the presence of nifedipine was the same as that under
baseline conditions (no inhibitor and unstimulated, dashed line
in Figure 6), suggesting that MYPT1 dephosphorylation may
be Ca2+-dependent consistent with the decrease in MYPT1
phosphorylation in response to Bay K8644 without inhibitor.
CPI-17 and Caldesmon Phosphorylation
The MLC phosphatase inhibitor CPI-17 is phosphorylated
by PKC. CPI-17 phosphorylation is usually increased during
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FIGURE 2 | Effect of pharmacological inhibitors on Bay K8644-stimulated force. (A) Effect of the LTCC inhibitor nifedipine (1 µM) on a 100 nM Bay K8644
induced contraction of the swine carotid artery. (B) Effect of the MLC kinase inhibitor ML-7 (10 µM) on a 100 nM Bay K8644 induced contraction. (C) Effect of the
Rho kinase inhibitor H-1152 (1 µM) on a 100 nM Bay K8644 induced contraction. (D) Effect of the pan-PKC inhibitor Bis (3 µM) on a 100 nM Bay K8644 induced
contraction. (E) Effect of the MAP kinase kinase inhibitor U0126 (10 µM) on a 100 nM Bay K8644 induced contraction. Inhibiting LTCC, MLC kinase, and Rho kinase
significantly prevented force development. Inhibiting PKC had no appreciable effect on force. Inhibiting MAP kinase kinase increased steady state force but did not
affect the rate of rise. Values shown are means ± SEM as a percent of the maximal force in response to 110 mM KCl-PSS. n = 10–20, each tissue strip was taken
from a different artery. One way repeated measures ANOVA was performed to detect differences between Bay K8644 induced contractions alone or in the presence
of the various pharmacological inhibitors. ∗∗p < 0.001 as compared to Bay K8644 in the absence of inhibitor.
contraction of VSM as it is one mechanism that increases
myofilament Ca2+ sensitivity. Caldesmon is a thin filament-
associated inhibitory protein that is phosphorylated by MAP
kinase and potentially PKC which reverses its’ inhibitory activity
(Barany et al., 1992; Childs and Mak, 1993; Wang, 2001).
Figure 7 shows CPI-17 and caldesmon phosphorylation in
response to Bay K8644 without inhibitor and in the presence
of nifedipine, ML-7, Bis, U0126, or H-1152. The lack of CPI-17
phosphorylation during Bay K8644 stimulation with or without
inhibitors suggests that PKC is not activated or that this particular
pathway is not involved in the observed increase in Bay K8644-
stimulated force and MLC phosphorylation. This agrees with
our earlier observation that inhibition of PKC did not affect
Bay K8644-induced force development (Figure 2D) or MLC
phosphorylation (Figure 4B). Phorbol-dibutyrate (PDBu) was
used as a positive control for CPI-17 phosphorylation as it
directly activates PKC. PDBu produced a significant increase in
CPI-17 phosphorylation demonstrating that the total lack of CPI-
17 phosphorylation was not an artifact due to electrophoresis or
Western blotting.
Bay K8644 stimulation alone or in the presence of the various
kinase inhibitors had no effect on phosphorylation of the thin
filament-associated protein caldesmon at Ser789 (Figure 7). The
level of phosphorylation was the same in basal unstimulated
tissues as it was in Bay K8644-stimulated tissues with or without
inhibitors. This suggests that thin filament disinhibition by
caldesmon phosphorylation is not involved in sustained LTCC-
mediated force in VSM. Inhibition of MAP kinase with U0126
had no effect on caldesmon phosphorylation.
DISCUSSION
The purpose of this study was to investigate intracellular signaling
involved in sustained, sub-maximal force induced by the LTCC
agonist, Bay K8644. Pharmacological inhibitors of LTCC, MLC
kinase, MAP kinase, PKC, and ROCK were used in order to
determine their involvement in sustained force.
Before we discuss the effects of the various inhibitors used
in this study, it should be pointed out that non-specificity of
pharmacological inhibitors is always a potential problem and the
accuracy of our data interpretation to a large extent depends
on how specific an inhibitor inhibits its intended target and
what other non-intended targets are affected. The inhibitors we
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FIGURE 3 | Steady state force in response to 100 nM Bay K8644 after
120 min of stimulation. Bay K8644-stimulated force at the termination of the
experiment (120 min) was compared to a maximal contraction in response to
110 mM KCl-PSS. Nifedipine (LTCC inhibitor), ML-7 (MLC kinase inhibitor),
and H-1152 (Rho kinase inhibitor) significantly decreased steady-state force.
Bis (PKC inhibitor) did not affect force. U0126 (MAP kinase kinase inhibitor)
significantly increased steady-state force. Addition of U0126 did not affect the
rate of force development, only the magnitude of steady-state force. Values
shown are the means ± SE and presented as a percent of the maximal
response to 110 mM KCL-PSS. n = 10–20, each tissue strip was taken from
a different artery. One way ANOVA with multiple comparisons against Bay
K8644 contractions in the absence of pharmacological inhibitors (Holm–Sidak
Method) was performed to determine significance. ∗∗p < 0.001 as compared
to Bay K8644 stimulation without inhibitor.
have chosen are commonly used in pharmacological studies and
according to the literature their specific is relatively high. But
none of the inhibitors used has only a single target. ML-7 is
more specific than its parent form ML-9 in inhibiting MLC kinase
(MLCK), however, it is able to inhibit other enzymes. It has
effects on cAMP-dependent protein kinases, PKC, and calcium
phosphodiesterase, although the binding affinity of ML-7 for
smooth muscle MLCK is ∼100 times higher than that for the
other enzymes (Saitoh et al., 1987). Although H-1152 is more
specific than its parent form HA-1077 and another Rho-kinase
inhibitor Y-27632, with a half maximal inhibitory concentration
(IC50) that is ∼10 times lower, however, H-1152 also inhibits
CaMKII, PKA, PKC, and PKG, but with IC50 values > 30
times higher than that for Rho-kinase (Tamura et al., 2005). H-
1152 also inhibits MLCK, but with an IC50 value greater than
1000 times that for Rho-kinase (Tamura et al., 2005). Bis (also
known as GF 109203x), besides inhibiting PKC, also inhibits
PKA, PKG, and tyrosine kinase, but with values of IC50 10
to 30 times greater than that for PKC (Toullec et al., 1991).
The MAP kinase kinase inhibitor (U0126) appears to be rather
specific, but it also inhibits PKC and extracellular signal-related
kinase (ERK1/2), although with IC50 150-750 times higher than
that for MAP kinase kinase (Duncia et al., 1998; Favata et al.,
1998).
Inhibition of MLC Kinase Increased MAP
Kinase
Inhibition of PKC with Bis or MLC kinase with ML-7 significantly
increased MAP kinase phosphorylation. The Bis effect has been
previously observed in our laboratory (Trappanese, 2012). The
significant increase in MAP kinase phosphorylation following
inhibition of MLCK was a novel finding. It suggests that MLCK
may have an inhibitory effect on MAP kinase activity. It is
also possible that this is due to some unknown enhancing
effect of ML-7 on MAP kinase kinase. It is also noticed that
nifedipine inhibited MLC phosphorylation (presumably through
inhibition of MLCK) (Figure 4) but failed to enhance MAP kinase
phosphorylation (Figure 5). This could be explained by assuming
that MAP kinase phosphorylation is calcium dependent.
Inhibition of MAP Kinase Kinase
Increased Force
The enhancement of force during inhibition of MAP kinase
kinase with U0126 was unexpected given that there was no
change in the levels of caldesmon phosphorylation. Based
on previous studies, U0126 should inhibit not only MAP
kinase kinase but also caldesmon phosphorylation (Adam and
Hathaway, 1993). MAP kinase regulates the thin filament-
associated protein caldesmon by phosphorylation at Ser789
relieving caldesmon’s inhibitory effect on actin-activated myosin
ATPase activity (Childs and Mak, 1993). MAP kinase-catalyzed
caldesmon phosphorylation can be activated by stretch (Franklin
et al., 1997) or contractile agonists such as KCl or phenylephrine
(Dessy et al., 1998). This study suggests that MAP kinase-
catalyzed caldesmon phosphorylation is not involved in the
signaling pathways activated in response to opening of LTCC.
Since inhibition of MAP kinase kinase increased force a possible
interpretation is that activated MAP kinase may have an indirect
inhibitory effect on force.
Inhibition of ROCK Decreased Force But
Not MLC Phosphorylation
ROCK has been shown to phosphorylate the regulatory MLC
at Ser19 (Kimura et al., 1996). This function, coupled with its
inhibition of MLC phosphatase activity, promotes contraction
in VSM. It has been demonstrated that ROCK is overactive in
VSM of hypertensive animal models and hypertensive humans,
and inhibiting ROCK results in normalization of blood pressure
(Uehata et al., 1997). Because ROCK plays an important role in
VSM contraction its role in LTCC-induced tone was of interest.
Inhibition of ROCK almost completely abolished Bay K8644-
induced force. However, inhibition of ROCK did not significantly
reduce MLC phosphorylation levels providing evidence for an
uncoupling of force and MLC phosphorylation. Additionally,
inhibition of ROCK decreased MYPT1 phosphorylation that
would remove the MYPT1-dependent inhibition of MLC
phosphatase activity and presumably result in a decrease in MLC
phosphorylation levels.
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FIGURE 4 | MLCSer19 phosphorylation measured by urea/glycerol-PAGE in the swine carotid artery in response to 100 nM Bay K8644 in the absence
and presence of pharmacological inhibitors. (A) Representative urea/glycerol-PAGE of phosphorylated and unphosphorylated MLC after 120 min of stimulation
with 100 nM Bay K8644 in the presence and absence of pharmacological inhibitors. Note the mobility shift between the phosphorylated and unphosphorylated
MLC. The top arrow points to the bands of unphosphorylated MLC, the bands at the level of the bottom arrow and below are phosphorylated MLC. The baseline
condition (unstimulated without any inhibitor) is not shown. (B) Quantitative results of several blots as shown in (A). Bay K8644 without inhibitor increased MLC
phosphorylation. Nifedipine (1 µM) and ML-7 (10 µM) abolished Bay K8644-dependent increases in MLC phosphorylation. Bis (3 µM) and H-1152 (1 µM) decreased
MLC phosphorylation to some extent but the decrease was not significant. U0126 (10 µM) did not alter Bay K8644-induced increases in levels of MLC
phosphorylation. For each condition fractional phosphorylation was obtained [i.e., the volume density of bands of phosphorylated/(phosphorylated +
unphosphorylated)], and each of the fractional phosphorylation was then divided by the fractional phosphorylation under baseline condition to obtain the fold
increase over the baseline. Values shown are the means ± SE and presented as a fold increase above basal MLC phosphorylation (unstimulated and without
inhibitor). n = 8–14, each tissue strip was taken from a different artery. One way ANOVA with multiple comparisons against Bay K 8644 contractions in the absence
of pharmacological inhibitors (Holm–Sidak Method) was performed to determine significance. ∗p < 0.05 as compared to Bay K8644 stimulation without inhibitor.
Bay K8644 Decreased MYPT1
Phosphorylation
MYPT1 phosphorylation significantly decreased in response
to Bay K8644 stimulation. None of the kinase inhibitors,
except for the ROCK inhibitor H-1152, altered the Bay K8644-
dependent decrease in MYPT1 phosphorylation. Bay K8644-
dependent decrease in MYPT1 phosphorylation was the opposite
of what was expected to occur. Because MYPT1 phosphorylation
inhibits MLC phosphatase activity it is logical to assume
that addition of a contractile agonist would increase MYPT1
phosphorylation in order to enhance force production without
additional Ca2+ influx. The only case in which MYPT1
phosphorylation was not significantly decreased was in the
presence of the LTCC inhibitor nifedipine. This suggests that
MYPT1 dephosphorylation may be catalyzed via a Ca2+-
dependent mechanism. How exactly MYPT1 is dephosphorylated
is unclear. Perhaps the sustained opening of LTCC caused by Bay
K8644 “over-sensitized” the Ca2+ sensitization mechanisms and
MYPT1 is dephosphorylated as a protective measure against high
levels of force production.
CPI-17 and Caldesmon Phosphorylation
In swine VSM PKCα and PKCδ are the dominant kinase
for CPI-17 phosphorylation (Eto et al., 2001). Bis (or
GF109203x) is a non-selective inhibitor of PKC, it inhibits
the α, βI, βII, γ, δ, and ε (Gekeler et al., 1996; Alessi,
1997). Activation of PKC, phosphorylation of CPI-17, and
subsequent inhibition of MLC phosphatase is part of the
Ca2+ sensitization pathway that promotes increased MLC
phosphorylation without requiring an increase in Ca2+ influx
or release (Li et al., 1998; Throckmorton et al., 1998). The
fact that CPI-17 was not phosphorylated in response to Bay
K8644 is surprising because PKC activation is a common
phenomenon in VSM contraction as evidenced by the fact
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FIGURE 5 | p42 and 44 MAP kinase phosphorylation levels in response to Bay K8644 in the absence and presence of pharmacological inhibitors in
the swine carotid artery. (A) Representative Western blot of p42 and p44 MAP kinase phosphorylation levels in response to 120 min of stimulation with 100 nM
Bay K8644 in absence and presence of nifedipine (1 µM, inhibitor of LTCC), ML-7 (10 µM, inhibitor of MLC kinase), Bis (3 µM, inhibitor of PKC), U0126 (10 µM,
inhibitor of MAP kinase kinase), and H-1152 (1 µM, inhibitor of ROCK). (B) Quantified results of several blots as shown in (A). Dashed line represents basal,
unstimulated MAP kinase phosphorylation levels for comparison. 120 min of stimulation with 100 nM Bay did not increase MAP kinase phosphorylation levels.
Nifedipine neither increased nor decreased MAP kinase phosphorylation levels during the Bay K8644 stimulation. ML-7 significantly increased both p42 and p44
MAP kinase phosphorylation levels. Similarly, Bis increased phosphorylation of both isoforms of MAP kinase. U0126 abolished basal levels of p42 and p44 MAP
kinase. H-1152 had no effect on MAP kinase phosphorylation during Bay K8644 stimulation. Values shown are means ± SEM and are presented as fold change
above or below basal values. n = 8–14, each tissue was taken from a different artery. One way ANOVA with multiple comparisons (Holm–Sidak Method) was used to
determine against values obtained during Bay K8644 stimulated in the absence of inhibitors. ∗∗p < 0.01 p42 MAP kinase phosphorylation levels as compared to
those during Bay K8644 stimulation without inhibitor. ††p < 0.01 p44 MAP kinase phosphorylation levels as compared to those during Bay K8644 without inhibitor.
that phorbol dibutyrate increases force in most VSM including
the swine carotid artery (Sato et al., 1992; Fulginiti et al.,
1993).
Caldesmon phosphorylation did not change during Bay
K8644 stimulation or with the inclusion of inhibitors. The
putative endogenous kinase for caldesmon is MAP kinase (Childs
and Mak, 1993). Upon phosphorylation, the inhibitory effect
exerted by caldesmon on actin-myosin ATPase is relieved,
allowing for an increase in cross bridge cycling. We expected
an increase in caldesmon Ser789 phosphorylation in response
to Bay K8644 stimulation, and inhibition of this increase in
caldesmon phosphorylation in the presence of U0126. The lack
of change, increase or decrease, in caldesmon phosphorylation
rules out a role for at least this thin filament protein in
the regulation of vascular tone in response to opening of
LTCC.
Limitations of the Study
The study relied on the use of pharmacological inhibitors.
Interpretations of the results therefore are bound by the
assumption that the inhibitors are highly specific, which, as
mentioned above, is not a strictly valid assumption. Findings
from the study, however, could serve as clues for further
investigation. Another limitation of the study is that we
only focused on the pathways related to the regulation
of contraction through actomyosin interaction. During the
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FIGURE 6 | MYPT1Thr850 phosphorylation levels after 120 min of stimulation with Bay K8644 in the absence or presence of pharmacological inhibitors
in the swine carotid artery. (A) Representative Western blot of MYPT1Thr850 in response to 100 nM Bay K8644 in the absence or presence of nifedipine (1 µM,
inhibitor of LTCC), ML-7 (10 µM, inhibitor of MLC kinase), Bis (3 µM, inhibitor of PKC), U0126 (10 µM, inhibitor of MAP kinase kinase), and H-1152 (1 µM, inhibitor
of ROCK). (B) Quantified results of several blots as shown in (A). Bay K8644 decreased MYPT1Thr850 phosphorylation levels from basal, unstimulated levels (dashed
line). This decrease was reversed or prevented by the addition of nifedipine. ML-7, Bis, and U0126 had no affect on the Bay K8644-dependent decrease in
MYPT1Thr850 phosphorylation levels. H-1152 significantly decreased MYPT1Thr850 phosphorylation levels as compared to the decrease induced by Bay K8644
stimulation. Values shown are the means ± SEM and presented as a fold change from basal values. n = 8–14 with each tissue taken from a different artery.
One-way ANOVA with multiple comparisons versus Bay K8644 treatment without inhibitor (Holm–Sidak Method) was performed to determine significance.
∗∗p < 0.001 as compared to Bay K8644 treated tissues.
prolonged (120 min) contraction induced by Bay K8644, other
pathways could have come into play, notably the pathways
related to the regulation of actin cytoskeletal function and
the muscle’s ability to maintain force through non-cross-
bridge mechanisms (Lehman and Morgan, 2012; Yamin and
Morgan, 2012; Lan et al., 2015). Both intracellular calcium
and MLC phosphorylation levels are known to vary with time
during contraction (Dillon et al., 1981). Many of the calcium-
dependent kinase activities are therefore likely to vary during
a prolonged contraction. Because we only made measurements
of kinase and protein phosphorylation at one time point
(120 min after stimulation), correlation of muscle force and
the levels of phosphorylation of the various protein and
enzymes only provides a snapshot of a complex and dynamic
process.
Overall Interpretation of Data and
Summary
In this study we have shown that opening of LTCC in response
to 100 nM Bay K8644 produced a sub-maximal sustained
contraction that was nifedipine-sensitive. Taken together our
data suggest that Ca2+ entry through LTCC activates the MLC
kinase resulting in MLC phosphorylation and force. In addition
a constitutively active ROCK and potentially ROCK that is
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FIGURE 7 | CPI-17Thr38 and caldesmon Ser789 phosphorylation levels after 120 min of stimulation with 100 nM Bay K8644 in the swine carotid artery.
(A) Representative Western blots showing CPI-17Thr38 and caldesmonSer789 phosphorylation levels during Bay K8644 stimulation in the absence or presence of
nifedipine (1 µM, inhibitor of LTCC), ML-7 (10 µM, inhibitor of MLC kinase), Bis (3 µM, inhibitor of PKC), U0126 (10 µM, inhibitor of MAP kinase kinase), and H-1152
(1 µM, inhibitor of ROCK). Phorbol 12,13-dibutyrate (PDBu) was used as a positive control for the measurement of CPI-17Thr38. (B) Quantified results of several blots
as shown in (A). Bay K 8644 stimulation did not increase phosphorylation values of either CPI-17Thr38. None of the pharmacological inhibitors increased or
decreased CPI-17Thr38 phosphorylation level compared with that of BayK. Only three conditions (BayK, U0126, and ML-7) are plotted against the positive control
(PDBu), they are all significantly different from the positive control. ∗∗∗p < 0.001. (C) Quantified results of several blots as shown in (A). Bay K 8644 stimulation did
not increase phosphorylation values of caldesmonSer789. None of the pharmacological inhibitors increased or decreased caldesmonSer789 phosphorylation level
compared with that induced by Bay K8644 stimulation.
activated by Ca2+ influx via LTCC (Ureña and Lopez-Barneo,
2012; Ouyang et al., 2014), sustains force by a MLC phosphatase-
and MLC phosphorylation-independent mechanism. MYPT1
dephosphorylation may be Ca2+-dependent. PKC catalyzed
CPI-17 phosphorylation and the resultant inhibition of MLC
phosphatase does not occur in response to LTCC opening
by Bay K8644. Inhibition of MLCK increases MAP kinase
phosphorylation suggesting that MLCK may have an inhibitory
or suppressive effect on MAP kinase activity. Moreover,
inhibition of MAP kinase enhances Bay K8644-dependent
force. Although caldesmon phosphorylation has been shown
to be increased by both membrane depolarization and agonist
activation, stimulation with Bay K8644 does not increase
caldesmon phosphorylation. These novel findings, especially the
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relationship between MLCK and MAP kinase, if
confirmed, may lead to a better understanding of VSM
function.
AUTHOR CONTRIBUTIONS
HE, RM: Made substantial contributions to the conception and
design of the work, the acquisition, analysis, abd interpretation
of data for the work. HE, RM: Drafted the work and
revised it critically for important intellectual content. CS: Made
substantial contribution to interpretation of data and revising the
manuscript. HE, CS: Provided final approval of the version to
be published. HE, CS: Agree to be accountable for all aspects of
the work and ensure that questions related to the accuracy or
integrity of any part of the work can be appropriately investigated
and resolved.
ACKNOWLEDGMENT
This study was supported in part by funds from NIDDK grant
DK 85734 to RM, and from CIHR operating grant MOP 13271
and NSERC DG to CS.
REFERENCES
Adam, L., and Hathaway, D. (1993). Identification of mitogen-activated protein
kinase phosphorylation sequences in mammalian h-caldesmon. FEBS 322,
56–60. doi: 10.1016/0014-5793(93)81110-L
Alessi, D. R. (1997). The protein kinase C inhibitors Ro 318220 and GF 109203X are
equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase.
FEBS Lett. 402, 121–123. doi: 10.1016/S0014-5793(96)01510-4
Alonso, M., Rico, I., Salaices, M., and Marin, J. (1989). Effects of the Ca agonists
Bay K 8644 and CGP 28392 on vascular smooth muscle tone. Gen. Pharmacol.
20, 827–831. doi: 10.1016/0306-3623(89)90338-8
Barany, K., Polyak, E., and Barany, M. (1992). Involvement of calponin and
caldesmon in sustained contraction of arterial smooth muscle. Biochem.
Biophys. Res. Commun. 187, 847–852. doi: 10.1016/0006-291X(92)91274-T
Catterall, W. (2000). Structure and regulation of voltage-gated Ca2+ channels.
Annu. Rev. Cell Dev. Biol. 16, 521–555. doi: 10.1146/annurev.cellbio.16.1.521
Childs, T., and Mak, A. (1993). Smooth muscle mitogen-activated protein
(MAP) kinase: purification and characterization, and the phosphorylation of
caldesmon. Biochem. J. 296, 741–751. doi: 10.1042/bj2960745
Cobine, C., Callaghan, B., and Keef, K. (2007). Role of L-type calcium channels and
PKC in active tone development in rabbit coronary artery. Am. J. Physiol. Heart
Circ. Physiol. 292, H3079–H3088. doi: 10.1152/ajpheart.01261.2006
Conti, M., and Adelstein, R. (1981). The relationship between calmodulin binding
and phosphorylation of smooth muscle myosin kinase by the catalytic subunit
of 3′:5′ cAMP-dependent protein kinase. J. Biol. Chem. 256, 3178–3181.
Davis, M., and Hill, M. (1999). Signaling mechanisms underlying the vascular
myogenic response. Physiol. Rev. 79, 387–414.
Dessy, C., Kim, I., Sougnez, C., Laporte, R., and Morgan, K. (1998). A role for
MAP kinase in differentiated smooth muscle contraction evoked by alpha-
adrenoreceptor stimulation. Am. J. Physiol. Cell Physiol. 75, C1081–C1086.
Dillon, P., Aksoy, M., Driska, S., and Murphy, R. (1981). Myosin phosphorylation
and the cross-bridge cycle in arterial smooth muscle. Science 211, 495–497.
doi: 10.1126/science.6893872
Duncia, J. V., Santella, J. B. III, Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E.,
et al. (1998). Olson, R. E. MEK inhibitors: the chemistry and biological activity
of U0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett. 8,
2839–2844.
Eto, M., Kitazawa, T., Yazawa, M., Mukai, H., Ono, Y., and Brautigan, D. L. (2001).
Histamine-induced vasoconstriction involves phosphorylation of a specific
inhibitor protein for myosin phosphatase by protein kinase C alpha and delta
isoforms. J. Biol. Chem. 276, 29072–29078. doi: 10.1074/jbc.M103206200
Eto, M., Ohmori, T., Suzuki, K., Furuya, K., and Morita, F. (1995). A novel protein
phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation
from porcine aorta media and characterization. J. Biochem. 118, 1104–1107.
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser,
W. S., et al. (1998). Identification of a novel inhibitor of mitogen-activated
protein kinase kinase. J. Biol. Chem. 273, 18623–18632. doi: 10.1074/jbc.273.
29.18623
Fleischmann, B., Murray, R., and Kotlikoff, M. I. (1994). Voltage window for
sustained elevation of cytosolic calcium in smooth muscle cells. Proc. Natl.
Acad. Sci. U.S.A. 91, 11914–11918. doi: 10.1073/pnas.91.25.11914
Folkow, B. (1989). Myogenic mechanisms in the control of systemic resistance:
introduction and historical background. J. Hypertens. Suppl. 7, S1–S4.
Franklin, M., Wang, C.-L., and Adam, L. (1997). Stretch-dependent activation and
desensitization of mitogen-activated protein kinase in carotid arteries. Am. J.
Physiol. Cell Physiol. 273, C1819–C1827.
Fransen, P., Van Hove, C., Van Langen, J., Schrijvers, D., Martinet, W., De
Meyer, G., et al. (2012). Contribution of transient and sustained calcium influx,
and sensitization to depolarization-induced contractions of the intact mouse
aorta. BMC Physiol. 12:9. doi: 10.1186/1472-6793-12-9
Fulginiti, J. R., Singer, H., and Moreland, R. (1993). Phorbol ester-induced
contractions of swine carotid artery are supported by slowly cycling
crossbridges which are not dependent on calcium or myosin light chain
phosphorylation. J. Vasc. Res. 30, 315–322. doi: 10.1159/000159012
Gekeler, V., Boer, R., Uberall, F., Ise, W., Schubert, C., Utz, I., et al. (1996). Effects
of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X
on P-glycoprotein-mediated multidrug resistance. Br. J. Cancer 74, 897–905.
doi: 10.1038/bjc.1996.454
Gollasch, M., Haase, H., Ried, C., Lindschau, C., Morano, I., Luft, F., et al.
(1998). L-type calcium channel expression depends on the differentiated state
of vascular smooth muscle cells. FASEB 12, 593–601.
Gopalakrishnan, V., Park, L., and Triggle, C. (1985). The effect of the calcium
channel agonist Bay K-8644 on human vascular smooth muscle. Eur. J.
Pharmacol. 113, 447–451. doi: 10.1016/0014-2999(85)90095-0
Herlihy, J., and Murphy, R. (1973). Length-tension relationship of smooth muscle
of the hog carotid artery. Circ. Res. 33, 275–283. doi: 10.1161/01.RES.33.
3.275
Horowitz, A., Menice, C., Laporte, R., and Morgan, K. (1996). Mechanisms of
smooth muscle contraction. Physiol. Rev. 76, 967–1003.
Katoch, S., and Moreland, R. (1995). Agonist and membrane depolarization
induced activation of MAP kinase in the swine carotid artery. Am. J. Physiol.
Heart Circ. Physiol. 269, H222–H229.
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., et al. (1996).
Regulation of myosin phosphatase by Rho and Rho-associated kinase. Science
273, 245–248. doi: 10.1126/science.273.5272.245
Lan, B., Deng, L., Donovan, G. M., Chin, L. Y., Syyong, H. T., Wang, L., et al. (2015).
Force maintenance and myosin filament assembly regulated by Rho-kinase in
airway smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L1–L10.
doi: 10.1152/ajplung.00222.2014
Lehman, W., and Morgan, K. G. (2012). Structure and dynamics of the actin-based
smooth muscle contractile and cytoskeletal apparatus. J. Muscle Res. Cell Motil.
33, 461–469. doi: 10.1007/s10974-012-9283-z
Li, L., Eto, M., Lee, M., Morita, F., Yazawa, M., and Kitazawa, T. (1998). Possible
involvement of the novel CPI-17 protein in protein kinase C signal transduction
of rabbit arterial smooth muscle. J. Physiol. 508, 871–881. doi: 10.1111/j.1469-
7793.1998.871bp.x
Moosmang, S., Schulla, V., Welling, A., Feil, R., Feil, S., Wegener, J., et al. (2003).
Dominant role of smooth muscle L-type channel Cav1.2 for blood pressure
regulation. EMBO 22, 6027–6034. doi: 10.1093/emboj/cdg583
Navedo, M., Amberg, G., Votaw, V., and Santana, L. (2005). Constitutively
active L-type Ca2+ channels. PNAS 102, 11112–11117. doi: 10.1073/pnas.05003
60102
Frontiers in Pharmacology | www.frontiersin.org 11 December 2016 | Volume 7 | Article 516
fphar-07-00516 December 22, 2016 Time: 16:34 # 12
Ets et al. L-Type Ca2+ Channels and Sustained Vascular Contraction
Navedo, M., Cheng, E., Yuan, C., Votaw, S., Molkentin, J., Scott, J., et al. (2010).
Increased coupled gating of L-type Ca2+ channels during hypertension and
Timothy syndrome. Circ. Res. 106, 748–756. doi: 10.1161/CIRCRESAHA.109.
213363
Nazer, M., and van Breemen, C. (1998). Functional linkage of Na+-Ca2+ exchange
and sarcoplasmic reticulum Ca2+ release mediates Ca2+ cycling in vascular
smooth muscle. Cell Calcium 24, 275–283. doi: 10.1016/S0143-4160(98)
90051-3
Ouyang, Q.-F., Han, Y., Lin, Z.-H., Xie, H., Xu, C.-S., and Xie, L.-D. (2014).
Fluvastatin upregulates the alpha-1C subunit of Cav1.2 channel expression in
vascular smooth muscle cells via RhoA and ERK/p38 MAPK pathways. Dis.
Markers 2014, 1–9. doi: 10.1155/2014/237067
Pesic, A., Madden, J., Pesic, M., and Rusch, N. (2004). High blood pressure
upregulates arterial L-type Ca2+ channels: is membrane depolarization
the signal. Circ. Res. 94, 97–104. doi: 10.1161/01.RES.0000131495.
93500.3c
Rubart, M., Patlack, J., and Nelson, M. (1996). Ca2+ currents in cerebral artery
smooth muscle cells of rat at physiological Ca2+ concentrations. J. Gen. Physiol.
107, 459–472. doi: 10.1085/jgp.107.4.459
Saitoh, M., Ishikawa, T., Matsushima, S., Naka, M., and Hidaka, H. (1987). Selective
inhibition of catalytic activity of smooth muscle myosin light chain kinase.
J. Biol. Chem. 262, 7796–7801.
Sato, K., Hori, M., Ozaki, H., Takano-Ohmuro, H., Tsuchiya, T., Sugi, H., et al.
(1992). Myosin phosphorylation-independent contraction induced by phorbol
ester in vascular smooth muscle. J. Pharmacol. Exp. Ther. 261, 497–505.
Smolock, E., Wang, T., Nolt, J., and Moreland, R. (2006). siRNA knock down of
casein kinase 2 increases force and cross-bridge cycling rates in vascular smooth
muscle. Am. J. Physiol. Cell Physiol. 292, C876–C885. doi: 10.1152/ajpcell.00343.
2006
Somlyo, A., and Somlyo, A. (1968). Electromechanical and pharmacomechanical
coupling in vascular smooth muscle. J. Pharmacol. Exp. Ther. 159,
129–145.
Sonkusare, S., Palade, P., Marsh, J., Telemaque, S., Pesic, A., and Rusch, N.
(2006). Vascular calcium channels and high blood pressure: pathophysiology
and therapeutic implications. Vasc. Pharmacol. 44, 131–142. doi: 10.1016/j.vph.
2005.10.005
Tamura, M., Nakao, H., Yoshizaki, H., Shiratsuchi, M., Shigyo, H., Yamada, H.,
et al. (2005). Development of specific Rho-kinase inhibitors and their clinical
application. Biochim. Biophys. Acta 1754, 245–252.
Thornloe, K., and Nelson, M. (2005). Ion channels in smooth muscle: regulators of
intracellular calcium and contractility. Can. J. Physiol. Pharmacol. 83, 215–242.
doi: 10.1139/y05-016
Throckmorton, D., Packer, C., and Brophy, C. (1998). Protein kinase C activation
during Ca2+-independent vascular smooth muscle contraction. J. Surg. Res. 78,
48–53. doi: 10.1006/jsre.1998.5368
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M.,
et al. (1991). The bisindolylmaleimide GF 109203X is a potent and selective
inhibitor of protein kinase C. J. Biol. Chem. 266, 15771–15781.
Trappanese, D. (2012). Mitogen-Activated Protein Kinase- and Protein Kinase
C-Catalyzed Phosphorylation in Vascular Smooth Muscle: Is It More Important
in the Regulation of Resting Tone or Stimulation-Induced Contraction?
Philadelphia, PA: Drexel University College of Medicine.
Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., et al.
(1997). Calcium sensitization of smooth muscle mediated by a Rho-associated
protein kinase in hypertension. Nature 389, 990–994. doi: 10.1038/40187
Ureña, J., and Lopez-Barneo, J. (2012). Metabotropic regulation of RhoA/Rho-
associated kinase by L-type Ca2+ channels. Trends Cardiovasc. Med. 22,
155–160. doi: 10.1016/j.tcm.2012.07.013
Wang, C.-L. (2001). Caldesmon and smooth muscle regulation. Cell Biochem.
Biophys. 35, 275–288. doi: 10.1385/CBB:35:3:275
Yamin, R., and Morgan, K. G. (2012). Deciphering actin cytoskeletal function in
the contractile vascular smooth muscle cell. J. Physiol. 590, 4145–4154. doi:
10.1113/jphysiol.2012.232306
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The handling Editor declared a shared affiliation, though no other collaboration,
with one of the authors CYS and states that the process nevertheless met the
standards of a fair and objective review.
Copyright © 2016 Ets, Seow and Moreland. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 12 December 2016 | Volume 7 | Article 516
